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PURPOSE: Tumour hypoxia activates hypoxia-inducible factor-1 (HIF-1) and indluences angiogenesis, cell survival and invasion. Prolyl
hydroxylase-3 (PHD3) regulates degradation of HIF-1a. The effects of PHD3 in tumour growth are largely unknown.
EXPERIMENTAL DESIGN: PHD3 expression was analysed in human pancreatic cancer tissues and cancer cell lines by real-time quantitative
PCR and immunohistochemistry. PHD3 overexpression was established by stable transfection and downregulation by short
interfering RNA technology. VEGF was quantified by enzyme-linked immunosorbent assay. Matrigel invasion assays were performed
to examine tumour cell invasion. Apoptosis was measured by annexin-V staining and caspase-3 assays. The effect of PHD3 on
tumour growth in vivo was evaluated in an established orthotopic murine model.
RESULTS: PHD3 was upregulated in well-differentiated human tumours and cell lines, and regulated hypoxic VEGF secretion. PHD3
overexpression mediated tumour cell growth and invasion by induction of apoptosis in a nerve growth factor-dependent manner by
the activation of caspase-3 and phosphorylation of focal adhesion kinase HIF-1 independently. In vivo, PHD3 inhibited tumour growth
by abrogation of tumour angiogenesis.
CONCLUSION: Our results indicate essential functions of PHD3 in tumour growth, apoptosis and angiogenesis and through
HIF-1-dependent and HIF-1-independent pathways.
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Pancreatic cancer is one of the most lethal human malignancies for
still unknown reasons (Jemal et al, 2007). Tumour hypoxia has
become an area of special interest as it has been correlated with
therapeutic resistance and increased invasion, metastasis and poor
outcome (Graeber et al, 1994; Buchler et al, 2004; Vaupel et al,
2005). Within this context the transcription factor Hypoxia-
inducible factor-1 (HIF-1) has been identified as a major regulator
of oxygen homoeostasis (Wang and Semenza, 1995; Wang et al,
1995). HIF-1 consists of two subunits: the hypoxia sensitive HIF-1a
subunit and the constitutively expressed HIF-1b subunit (Wang
and Semenza, 1995; Wang et al, 1995). Under normoxic conditions
HIF-1a is subject to rapid degradation by means of hydroxylation
of specific proline residues that enables binding of the von
Hippel–Lindau protein and the formation of an E3 ubiquitin
ligase complex that targets HIF-a for proteosomal degradation
(Semenza, 2007).
Three prolyl hydroxylase domain containing proteins, PHD1,
PHD2 and PHD3 (PHDs, HIF-PHDs or Egl-9 homologues) mediate
oxygen-dependent degradation of HIF-1a through von Hippel–
Lindau protein (Epstein et al, 2001; Metzen and Ratcliffe, 2004).
All three PHDs catalyse site-specific hydroxylation of HIF-a at
Pro-564. Under hypoxic conditions PHDs show reduced enzyme
activity resulting in stabilisation of HIF-1a. The expression of
PHDs is regulated by a variety of stimuli, including hypoxia, which
induced PHD2 and PHD3 expression (Epstein et al, 2001; Bruegge
et al, 2007). Hypoxia-induced PHD3 expression results in
enhanced rates of HIF-1a degradation. It is interesting that
PHD3 appears to be a direct target of HIF-1 serving as a negative
feedback mechanism (Marxsen et al, 2004). However, the
physiological role is not well understood.
Only little is known about PHD3 in human cancer growth. In the
case of pancreatic cancer a recent report found that PHD3 is
overexpressed in pancreatic cancer and might influence patient’s
survival (Metzen and Ratcliffe, 2004; Bruegge et al, 2007; Gossage
et al, 2010). In the present study, we focus on the regulatory
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sfunction of PHD3 in tumour growth and progression, including its
role in apoptosis and angiogenesis in vitro and in vivo.
PATIENTS AND METHODS
Patients
Human pancreatic tissue specimens were obtained from 62
patients who underwent resection for ductal adenocarcinoma of
the pancreas and 20 organ donors, where no recipients for
transplantation were present. The study protocol was approved by
the Ethics Committee of the University of Heidelberg, Germany.
Cell culture
Pancreatic cancer cell lines Capan-1, Capan-2, MIA PaCa-2 and
PANC-1 were obtained from the American Tissue Type Culture
Collection (Rockville, MD, USA) and cultured as described
(Buchler et al, 2005). For hypoxia studies a modular incubator
chamber was flushed for 20min with a gas mixture consisting of
0.75% O2, 10% CO2 and 89.25% N2. Recombinant human
nerve growth factor (NGF) was purchased from R&D Systems
(Minneapolis, MN, USA). Hydroxylase inhibitor dimethyloxaloyl-
glycine (DMOG) was obtained from Biomol GmbH (Hamburg,
Germany) and used at 40mM. 3-(50-hydroxymethyl-20-furyl)-1-
benzyl indazole (YC-1) was purchased from AG Scientific Inc. (San
Diego, CA, USA), resuspended in DMSO at a stock concentration
of 120mgml
 1, and stored at  301C. YC-1 was added at a
concentration of 30mM 1h before the assay. The concentration of
30mM YC-1 was chosen on the basis of the previous experiments,
in which hypoxic accumulation of HIF-1a protein levels were
reduced by 470% in both cell lines investigated (Supplementary
Figure).
RNA preparation and real-time quantitative PCR qRT-PCR
All reagents and equipment for mRNA and cDNA preparation
were purchased from Roche Applied Science (Mannheim,
Germany). The mRNA was isolated by automated MagNA Pure
LC instrument and cDNA was generated. RT-PCR was performed
with the LightCycler FastStart DNA SYBR Green kit as described
previously (Buchler et al, 2005). The number of specific transcripts
was calculated from the standard curve of two housekeeping
genes, cyclophilin B and hypoxanthine phosphoribosyltransferase.
The data of two independent analyses for each sample and
parameter were averaged and presented as adjusted transcripts per
ml of cDNA.
Generation of PHD3-overexpressing PANC-1 and MIA
PaCa-2 cells
PANC-1 and MIA PaCa-2 cells were converted into PHD3-
overexpressing cells by stable transfection of the pEGFP-N1
(Clontech, Palo Alto, CA, USA) expression plasmid carrying full-
length PHD3 cDNA using the TransFectin Lipid Reagent (Bio-Rad
Laboratories, Mu ¨nchen, Germany). Selection was done in G418
containing culture medium resulting in a pool of transfected cells.
Empty pEGFP-N1 plasmids were transfected as a negative control.
Short interfering RNA (siRNA) treatment
Cells were less than 50% confluent and transfected with 5.0nM
siPHD3 at 24 and 48h using Oligofectamine (Invitrogen,
Darmstadt, Germany) according to the manufacturer’s instruc-
tions. Sequences of PHD3 siRNA were (sense: 50-GUACUUU
GAUGCUGAAGAAUU-30; antisense: 50-UUCUUCAGCAUCA
AAGUACUU-30, Genebank accession number: EGLN3NM_022073)
and luciferase (siControl scrambled Non-Targeting siRNA)
purchased from Applied Biosystems (Applera Deutschland GmbH,
Darmstadt, Germany).
Apoptosis measurement and caspase-3 activity assays
For annexin-V-binding studies an annexin-V-FLOUS Staining Kit
(Boehringer Mannheim GmbH, Mannheim, Germany) was used
as previously described in detail (Buchler et al, 2003a). Annexin-
V-positive and propidium-iodide-positive cells were considered as
necrotic cells, whereas annexin-V-positive and propidium-iodide-
negative cells were counted as apoptotic cells. Details of the
caspase assays were also previously described (Buchler et al,
2003a). Data were expressed as mol AMC permg protein per
minute and given as means±s.e. for at least three preparations.
Caspase-3 substrate and caspase-3 inhibitor Z-Val-Ala-Asp-
fluoromethylketone were purchased from Calbiochem (San Diego,
CA, USA).
Protein studies
Western blot analyses were carried out as previously described
(Buchler et al, 2003a). Briefly a mouse monoclonal anti-HIF-1a
(diluted 1:750, Transduction Laboratories, San Diego, CA, USA),
a mouse monoclonal anti-a-tubulin (diluted 1:750, Santa Cruz
Biotechnology, Heidelberg, Germany), a rabbit polyclonal
anti-human PHD3 antibody (diluted 1:200; AB4562, Abcam,
Cambridge, UK) were used. Polyclonal antibodies to focal adhesion
kinase (FAK) and to the phosphoprotein p-FAK were from Santa
Cruz Biotechnology.
Immunohistochemistry was done manually as previously
described (Buchler et al, 2003b). The rabbit polyclonal anti-human
PHD3 antibody (diluted 1:200; AB4562, Abcam), the mouse
monoclonal anti-HIF-1a (diluted 1:100 Transduction Labora-
tories) and for carbonic anhydrases IX (CAIXs) a murine mono-
clonal antibody M75 recognising the N-terminal domain of CAIX
in dilution of 1:250 were used as primary antibodies. Tissues from
normal human pancreas and human pancreatic cancer were fixed
in formalin and embedded in paraffin. Tissue sections (5mm)
were deparaffinised and rehydrated. After deparaffinisation and
rehydration antigen retrieval was performed by cooking in
0.1moll
 1 sodium citrate buffer for 25min, followed by treat-
ment with 3% hydrogen peroxide solution to block endogenous
peroxidase activity. Incubation with primary antibodies was
carried out over night at 41C. After standard washing steps
slides were subsequently incubated with a biotinylated secondary
antibody and streptavidin-peroxidase. Slides were exposed to
3.30-diaminobenzidine tetrahydrochloride (Dako GmbH, Hamburg,
Germany) for colour development and counterstained with
hematoxylin.
Quantification of immunohistochemical staining was done by
using a scale ranging from 0 to 3 dependent upon the number of
positively stained (tumour) cells. PHD3 expression was analysed
according to the percentage of cells showing cytoplasmic
positivity. The grading was done as following: grade 0, 0–10%;
grade 1þ, 10–20%; grade 2þ, 20–50%; and grade 3þ, 450%.
The degree of monoclonal antibody reactivity in individual tissue
sections was considered positive if unequivocal staining of the
cytoplasm was seen in more than score 2þ. The slides were
analysed independently by two investigators blinded to the
underlying clinicopathological condition.
Determination of VEGF protein levels in cell supernatant was
done as described (El Fitori et al, 2007). MIA PaCa-2 and PANC-1
cells were seeded at 2.5 10
6 cells per 100mm tissue culture plate
and equal densities for each cell line were analysed. Cells were
grown for 24h in DMEM medium supplemented with 10% FBS,
washed three times with PBS and changed to exactly 10ml of
DMEM medium supplemented with 1% FBS. Identical cultures for
normoxic and hypoxic culture were analysed. Cells were harvested
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the amount of VEGF protein in the supernatant of cells was
determined with an enzyme-linked immunosorbent assay kit
(R&D Systems) according to the manufacturer’s instructions.
The VEGF protein levels was expressed as per gram of VEGF
protein per 10
5 cells.
Invasion assay
Cell invasion was studied using the BioCoat Matrigel Invasion
Chambers (Becton Dickinson, Bedford, MA, USA). 2.5 10
4 cells
were seeded into the upper chamber of the invasion chambers and
incubated for 24h for consolidation after seeding. For hypoxia
studies (48h), the BioCoat Matrigel invasion chamber was placed
in the hypoxic chamber that was flushed for 20min with a gas
mixture consisting of 0.75% O2, 10% CO2 and 89.25% N2. Cells
adherent to the lower surface were fixed in 75% methanol mixed
with 25% acetone and then stained with 1% Toluidine blue. Cells
were counted under a microscope at  200 magnification. The
invasion index was expressed as the ratio between the numbers of
invaded test cells to the number of invaded control cells.
Orthotopic pancreatic cancer model
An orthotopic metastatic nude mouse (BALB/cA) model was used
as described (Fu et al, 1992; Buchler et al, 2007). After 6 weeks
animals underwent autopsies. Metastatic tumour spread was
determined macroscopically in all thoracic, abdominal, retro-
peritoneal and pelvic organs, and all suspicious lesions were
confirmed by microscopic analysis. Metastatic spread was quanti-
fied by counting the different organs, which contained metastatic
lesions. Thus, every point in the metastatic score represented a
different organ of metastatic tumour spread (Buchler et al, 2004).
The tumour volume was calculated as described previously using
the following formula: tumour volume¼0.5 (length width 
depth) (El Fitori et al, 2007).
Assessment of microvessel density in xenograft tumours
For assessment of vascularity, frozen sections, each 5mm thick,
were cut and immunostaining of the endothelial cells were done
with anti-mouse CD31 antibody (BD Pharmingen, CA, USA) as
previously described (Buchler et al, 2007). Stained tissue speci-
mens were analysed by two independent observers unaware of the
animal’s status. Microvessel density was determined as described
by Vermeulen (Vermeulen et al, 2002).
Statistical analysis
Experiments were done in triplicates and repeated at least two
times. Results are expressed as mean±s.e. Statistical significance
was determined by Student’s t-test (Po0.05).
RESULTS
PHD3 is upregulated in human pancreatic cancer samples
Localisation of PHD3 expression in human tissue specimens was
analysed by immunohistochemistry. In normal pancreatic tissue
sections immunoreactivity for PHD3 was present in pancreatic
acini and pancreatic islet cells (not shown). In contrast, pancreatic
cancer tissues exhibited in well-differentiated specimens a strong
PHD3 immunoreactivity in ductal cancer cells in which a primarily
cytoplasmic staining pattern was present (Figure 1A–D). Strong
immunoreactivity was also observed in cancer cells approaching
nerves within the tumour without histological signs of tumour
invasion into these nerves (Figure 1C and D). Overall there was a
clear trend that better-differentiated tumours exhibited a stronger
PHD3-staining intensity when compared with less-differentiated
tumour specimens. A possible relationship between PHD3
expression, HIF-1 activation and CAIX activation was assayed
using serial slides. There was a regular co-localisation of HIF-1
and CAIX, but no clear correlation was detectable with PHD3 (not
shown).
PHD3 mRNA expression was determined in 20 normal pancreatic
tissue samples, 62 pancreatic cancer tissue samples, 16 specimens of
liver metastases and 10 lymph-node metastases of pancreatic cancer.
(Figure 1E). In comparison to normal pancreatic tissues PHD3
mRNA expression was significantly elevated in pancreatic cancer
tissues (Po0.01). The average replicate number of PHD3 mRNA
was 96±76 in normal pancreas. In contrast, a more than 10-fold
increased PHD3 mRNA expression level was found in pancreatic
cancer specimens with an average replicate number of 1183±219
mRNA copies per ml (Figure 1E). Similar to the observation in
immunohistochemical analysis, there was a clear trend to higher
PHD3 mRNA levels in more-differentiated tumour specimens.
Well-differentiated tumour samples had significantly higher PHD3
mRNA levels when compared with undifferentiated tumour samples
(Po0.0001) (Figure 1F). Similarly metastatic lesions as found in
liver metastases and lymph nodes expressed higher levels of PHD3
mRNA (Po0.05), when compared with normal pancreatic tissue
(Figure 1E).
PHD3 mRNA expression in cultured pancreatic cancer cell
lines
PHD3 mRNA expression in cultured pancreatic cancer cell lines
Capan-1, PANC-1 and MIA PaCa-2 was also determined by
qRT-PCR. PHD3 mRNA expression was detected in the well-
differentiated tumour cell lines Capan-1 (83±8copies per ml) and
Capan-2 (145±24copies/ml). The less-differentiated PANC-1 cell
line expressed only low levels of PHD3 mRNA (16±3copies per
ml), whereas the undifferentiated MIA PaCa-2 cell line was entirely
devoid of PHD3 mRNA expression (Figure 2A).
PHD3 directly modulates hypoxic HIF-1 target gene
expression
PHD3 has been shown to catalyze proteolytic degradation HIF-1a
and inhibition of VEGF gene expression. As pancreatic cancer
grows under hypoxic conditions, it was tested whether PHD3
overexpression influences HIF-1a stabilisation and VEGF secre-
tion. For this purpose PHD3 expression was induced in cell lines
with low or absent PHD3 expression PHD3 (MIA PaCa-2 and
PANC-1). Both cell lines were stably transfected either with a
PHD3 expression vector or an empty pEGFP/N1 vector for control
experiments. Upon cell transfection, PHD3 expression was stably
induced in both cell lines (Figure 2B). The functional relevance was
tested by exposing cells to hypoxia for 16h. HIF-1a protein was
downregulated by PHD3 overexpression under hypoxic conditions
but, nevertheless, HIF-1a protein was still detectable at low levels
(Figure 2C). Conversely, Capan-1 and Capan-2 cells expressed high
PHD3 mRNA levels constitutively. Therefore, experimental down-
regulation of PHD3 was achieved by using specific siRNAs directed
against PHD3. Upon siRNA treatment, PHD3 protein was not
detectable by western blot analysis under normoxia in Capan-1
and -2 cells, but a slight protein band was detectable under hypoxic
conditions. To test whether HIF-1 target gene expression was
affected by modulation of PHD3 expression we assessed VEGF
protein levels (Figure 2E and F). Under normoxic conditions PHD
regulation had no effect on VEGF secretion (Figure 2E and F).
Hypoxic culture conditions itself increased VEGF protein secretion
in all cell lines. Overexpression of PHD3 in MIA PaCa-2 and
PANC-1 cells significantly reverted hypoxic induction of VEGF
secretion (Po0.05). Reversely downregulation of PHD3 by siRNA
in Capan-1 and -2 cells expressing PHD3 resulted in a marked
PHD3: a hypoxic sensor in pancreatic cancer growth
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sincrease of VEGF secretion when compared with mock transfected
cells (Figure 2F).
PHD3 modulates tumour cell growth, invasion and cell
morphology
Uniformely hypoxic cell culture conditions per se led to growth
retardation in all cell lines (Figure 3A). Knockdown of PHD3 using
siRNA against PHD3 caused an increase in cell number under
hypoxia in Capan-1 and Capan-2 cells when compared with cells
treated with scrambled siRNAs or wild-type cells (Figure 3A).
Overexpression of PHD3 in MIA PaCa-2 and PANC-1 cells
significantly accelerated growth suppression under hypoxic
conditions when compared with wild-type or mock-transfected
(empty pEGFP/N1 vector) cells (Figure 3A). The tendency that
PHD3 expression exhibited growth-suppressive effects was seen
under conditions of normoxia as well (Figure 3A). Whether these
observations were because of the HIF-1 activation was tested by
using the HIF-1 inhibitor YC-1, but no clear effect of YC-1 on cell
growth was detectable (data not shown). In Matrigel-based
invasion assays overexpression of PHD3 in MIA PaCa-2 and
PANC-1 cells significantly reduced tumour cell invasion (Po0.05).
In the case of PANC-1 a 27.5% reduction of cell invasion was
observed and in the case of MIA PaCa-2 invasion was reduced by
43.7% (Figure 3B). Furthermore, the PHD3-transfected MIA PaCa-
2 and PANC-1 cells exhibited a clear change in cell morphology
and growth pattern, showing a more scattered and dispersed
cell-growth pattern when compared with controls (Figure 3C). On
the basis of this observation we tested whether changes in cell
growth also led to changes in cell’s contractility, as enhanced
contractility and formation of stress fibres are required for cell
migration and matrigel invasion. Visualisation of stress fibres was
achieved by Alexa Fluor 488 phalloidin incorporation after
transfection of MIA PaCa-2 and PANC-1 cells. PHD3 transfection
induced the formation of stretched bundles of stress fibres when
compared with control cells (Figure 3C). Because FAK activity has
a key role in actin polymerisation and stress fibre formation, we
tested the effect of PHD3 overexpression on FAK phosphorylation
in MIA PaCa-2 and PANC-1 cells. Upon PHD3 overexpression
there was a clear increase in phospho-FAK, but no increase in total
FAK was detectable (Figure 3D). The effect required PHD3
hydroxylase activity, as DMOG treatment abrogated FAK phos-
phorylation. DMOG is a well-characterised PHD inhibitor (DMOG)
used in a concentration of 40mM (Biomol GmbH). In contrast, FAK
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Figure 1 PHD3 expression in human pancreatic cancer tissue specimens: PHD3 immunohistochemistry of pancreatic ductal adenocarcinoma specimens
(A–D). qRT-PCR (E) of normal human pancreatic tissue and tissue specimens of primary tumours, liver and lymph node metastases (E). Correlation of
PHD3 mRNA expression levels with tumour grading (F). Po0.05 and Po0.01 indicates statistical significance.
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sphosphorylation was seen independent of HIF-1, as the HIF-1
inhibitor YC-1 did not affect FAK phosporylation (Figure 3D).
PHD3-induced NGF-dependent apoptosis by activation of
caspase-3 activity
The morphology of cells overexpression PHD3 was quite distinct
(Figure 3C) and it appeared that some of these cells undergo
apoptosis. Therefore, one likely reason for reduced tumour cell
invasion might be the induction of apoptosis (Figure 4A–F). Upon
PHD3 expression apoptosis increased in MIA PaCa-2 and PANC-1
cells sharply (Figure 4B). Treatment with DMOG reverted the
proapoptotic effect of PHD3 expression almost completely in
PANC-1 and MIA PaCa-2 cells suggesting that apoptosis required
PHD3 activity. In order to confirm that PHD3 expression regulates
apoptosis siRNA experiments were performed. Suppression of
PHD3 expression in Capan-1 and Capan-2, led to a decrease in
apoptosis in these cell lines (Figure 4A). These findings suggest
that PHD3 has growth-suppressive and anti-invasive properties
triggered by the induction of apoptosis. This process was seen
independently of HIF-1, as YC-1 treatment did not affect apoptosis
in these cell lines (data not shown). The mechanism by which
apoptosis is mediated was further analysed by caspase-3 assays, as
caspase-3 activation is involved in apoptosis in pancreatic cancer
cells (Buchler et al, 2003a). Therefore, we analysed whether PHD3
activity is linked to activation of caspase-3 and found that PHD3
overexpression increased caspase-3 activity (Figure 4D). Further
evidence that caspase-3 activity is controlled by PHD3 was gained
in siRNA experiments suppressing constitutive PHD3 activity in
Capan-1 and -2 cell lines, in which caspase-3 activity was inhibited
upon PHD3 suppression (Figure 4C). PHD3 increased caspase-3
activity as seen by the appearance of the cleaved 20kD active
caspase fragment (Figure 4E). Activation of caspase-3 was
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Figure 2 Modulation of PHD3 expression in human pancreatic cancer cell lines and hypoxic gene expression: PHD3 mRNA levels in pancreatic cancer
cell lines were measured by qRT-PCR (A). PHD3 transfection increased PHD3 protein levels in MIA PaCa-2 and PANC-1 cells (B). HIF-1 western blot
analysis of PHD3 and control tranfected cells after 16h of hypoxia (C). Targeting PHD3 expression by siRNA. PHD3 western blot of siPHD3 or control
siRNA-treated Capan-1 and Capan-2 cells (D). Whole-cell extracts were resolved on 10% SDS polyacrylamide gels, proteins were transferred to
nitrocellulose membranes and probed with antibodies against PHD3. Incubation with the g-tubulin monoclonal antibody was performed as a loading control
(B, D). VEGF secretion determined by enzyme-linked immunosorbent assay (E). Capan-1 and -2 cells were treated by siRNA to suppress PHD3 expression,
whereas MIA PaCa-2 and PANC-1 cells were transfected with a PHD3 expression vector to restore PHD3 expression (F). *Po0.05 indicates statistical
significance of hypoxic vs normoxic treatment;
#Po0.05 indicates statistical significance within the hypoxic treatment panel.
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sinhibited by Z-Val-Ala-Asp-fluoromethylketone, a broad-spectrum
caspase inhibitor, which blocked PHD3-induced caspase activation
(Figure 4E). Similarly caspase-3 activation was not altered in cells
treated with YC-1 suggesting that the effect of PHD3 on apoptosis
was independent of HIF-1 (data not shown).
Because of the in vivo observation that PHD3 immunoreactivity
was strongly stained next to nerves in pancreatic cancer we
determined the role of NGF in PHD3-mediated apoptosis, as
previous reports indicated that NGF influences apoptosis (Lee
et al, 2005). NGF has previously been shown to be a direct
mitogenic factor in pancreatic cancer and presumably influences
perineural cancer invasion and metastatic spread (Zhu et al, 1999).
PHD3-induced apoptosis was suppressed by addition of increasing
doses of NGF with the maximum survival observed at 200ngml
 1
(Figure 4F). Serum starvation and NGF withdrawal with PHD3
overexpression caused the highest apoptotic rate in both MIA
PaCa-2 and PANC-1 cells, suggesting that NGF suppresses
PHD3-triggered apoptosis. To test whether this effect was specific
for NGF and not a general phenomenon among growth factors
we also tested whether VEGF (10ngml
 1), FGF-2 (5ngml
 1)o r
PDGF-AB (20ngml
 1) and found no effect of caspase-3 activity
(data not shown).
In vivo, PHD3 regulates tumour growth and angiogenesis
in an orthotopic mouse model
To determine the effect of PHD3 overexpression on tumour growth
and angiogenesis in vivo, we used an orthotopic mouse model.
A pool of selected PHD3 overexpressing MIA PaCa-2 and PANC-1
cells were injected into donor mice for subcutaneous tumour
formation. After a 4-week period of subcutaneous tumour
formation, one small tumour fragment was used for orthotopic
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Figure 3 HD3 negatively regulates pancreatic cancer growth and tumour cell invasion: (A) Cells were cultured under regular culture conditions (nx; blue
lines) or conditions of hypoxia (hypx; black line) for the indicated time. Cell count was done as described and untreated normoxic wild-type (wt) cells were
considered as reference and set as 1.0. Knockdown of PHD3 expression in Capan-1 and -2 was achieved by siRNA against PHD3 sequences and compared
with scrambled siRNA sequences or untreated (wt) cells. Overexpression of PHD3 in MIA PaCa-2 and PANC-1 cells was achieved by cell transfection with
a full-length PHD3 cDNA cloned into a pEGFP/N1 expression vector (A). (B) Matrigel-based invasion assay. Pancreatic cancer cells were grown for 48h
under hypoxic culture conditions and the assay performed and calculated as described in Materials and methods. Wild-type cells were set as 1.0 and served
as reference. (C) Upon cell transfection, the cell shape of MIA PaCa-2 cells changed with a more scattered cell growth and some cells detaching from the
surface (C). Phase contrast images of PHD3 overexpressing MIA PaCa-2 cells showing clustered morphology in the control group (C left) and scattered cell
growth in the PHD3 expressing cells (C right). These images were acquired with a  10 objective. The insert in C shows stress fibre formation after PHD3
overexpression. Human MIA PaCa-2 cells were seeded on chamber slides (10000 cells/well) MIA PaCa-2 wild-type cells (left insert) and PHD3-transfected
cells 24h after cell transfection (right insert). Cells were fixed, permeabilised, and stained with Alexa Fluor 488 phalloidin, which shows F-actin sites.
(D) Effect of PHD3 on FAK phosphorylation in MIA PaCa-2 and PANC-1 cells. Cells were cultured for 24h in DMEM supplemented with 0.5% FBS and the
indicated inhibitors for PHD3 (dimethyloxaloylglycine) and HIF1a (YC-1) were added and then cells grown for an additional 12h in serum-free medium.
Cell lysates were prepared and subjected to immunoblot analysis with antibodies to FAK or to phosphorylated FAK (p-FAK). * or
# indicates Po0.05 when
compared with wt cells.
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stumour transplantation into the tail of the mouse pancreas.
Around 6 weeks after tumour orthotopic tumour induction, mice
were killed. Recombinant overexpression of PHD3 inhibited
pancreatic cancer growth in nude mice substantially (Figure 5A),
as the average sizes of PHD3 overexpressing tumours was
significantly smaller when compared with control xeonograft
tumours (Po0.05). The growth inhibitory activity of PHD3 was
seen in both cell lines tested (Figure 5A). First, we tested whether
growth inhibition was due to increased apoptosis in PHD3-
overexpressing xenografts. Tunel staining did not reveal any
difference between the different xenografted cells. As PHD3
inhibited VEGF production in vitro we assessed microvessel
density of the harvested tumour xenografts (Figure 5B) and found
a markedly decreased microvessel density in those xenograft
tumours derived from PHD3-overexpressing cell clones
(Figure 5B). PHD3 overexpression reduced metastatic tumour
growth in mice bearing MIA PaCa-2 xenograft tumours with a
metastatic score of 0.68±0.17 vs 1.4±0.25. No significant
difference was seen in the metastatic score of PANC-1 xenografted
tumours.
DISCUSSION
Hypoxia is a key microenvironmental condition in growth and
metastasis of pancreatic cancer with HIF as the key molecular
player in the process of adaptation to low oxygen levels (Rankin
and Giaccia, 2008). HIF is a heterodimer of a constitutively
expressed HIF-1b subunit, and one of three oxygen-regulated
HIF-a subunits (HIF-1a, HIF-2a or HIF-3a). HIF activation is a
%
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Figure 4 Effects of a PHD3 overexpression on apoptosis in pancreatic cancer cells. Effects of modulation of PHD3 expression on apoptosis (A and B)
and caspase-3 activation (C–F). In A and B Annexin-V staining was used to quantify apoptosis and in C and D caspase-3 activity was assayed as described
in methods. The clear bar in panel A and C shows the results of native Capan-1 and -2 cells. The dark bar represents siRNA PHD3 experiments and the
grey bar cells treated with scrambled siRNA moieties. In panel B and D the clear bar represents cells transfected with the empty vector (pEGFP), the grey
bar reflects the results obtained by PHD3 overexpression and the black bar reflects the results obtained of PHD3-transfected cells treated with
dimethyloxaloylglycine for 24h before analysis. (E) MIA PaCa-2 and PANC-1 cells were cultured for 72h. Cell lysates were obtained and subjected to
western blot analysis. Activation of caspase-3 was manifested by the decrease in pro-caspase-3 (32kD) and concomitant increase in active caspase-3
fragment (20kD). The pan-caspase inhibitor Z-Val-Ala-Asp-fluoromethylketone (50mM, þZ-VAD) was used to inhibit caspase-3. In panel F experiments
were performed as described in 35-mm diameter dishes. 3 10
4 cells per 35-mm dish were inoculated in 2ml of medium containing 10% FCS. After 24h,
cells were washed twice with serum-free medium. Next day, the medium was replaced with 2ml of 0.5% serum containing medium with addition of NGF at
the indicated doses. Values represent means±s.e. for at least three independent experiments. *Po0.05 indicated statistically significant differences
compared with control-treated cells.
#Po0.05 indicates statistically significant differences in comparison to PHD3-modulated cells.
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smulti-step process involving HIF-a stabilisation, nuclear trans-
location, heterodimerisation and transcriptional activation
(Pouyssegur et al, 2006). However, HIF does not directly sense
variations in oxygen tension. Instead, there are two types of
oxygen sensors that control HIF action: The PHD domain proteins
(PHD1-3) and the factor inhibiting HIF-1 (FIH) – an asparaginyl
hydroxylase. PHD1-3 proteins hydroxylate two prolyl residues
in the human HIF-1a region (oxygen-dependent degradation
domain) (Epstein et al, 2001; Jaakkola et al, 2001). This HIF-a
modification specifies rapid interaction with the von Hippel–
Lindau protein, a component of an E3 ubiquitin ligase complex.
Subsequently, HIF-a subunits become marked with polyubiquitin
chains and destructed by the proteasomal system. The FIH
hydroxylates an asparagine residue (N803) in the most carboxy-
terminal transcriptional activation domain of human HIF-1a. This
modification abrogates carboxy-terminal transcriptional activation
domain interaction with transcriptional co-activators, such as
p300/CBP. As PHDs have a much lower affinity for oxygen than
FIH, PHDs will be inactivated at oxygen values that still maintain
FIH activity and, therefore, keep carboxy-terminal transcriptional
activation domain under repression. Thus, the two TADs, together
with the oxygen-sensitive discriminator FIH, constitute a cellular
device that allows fine-tuning of specific HIF gene expression
along a hypoxic gradient.
Clinically only little is known on the function of the PHD3 gene
with regard to cancer biology in general and pancreatic cancer
growth as well (Dayan et al, 2006).
In human tumour specimens of pancreatic cancer PHD3 was
more than 10-fold upregulated. It is interesting that the upregula-
tion was most pronounced in tumours that were well differ-
entiated. Undifferentiated tumours expressed lower PHD3 mRNA
levels than the well-differentiated specimens. Similarly, metastatic
lesions exhibited higher PHD3 mRNA levels than normal
pancreatic tissue, but less than the average cancer sample,
indicating a gradual loss of PHD3 mRNA during the process of
tumour de-differentiation and metastasis. This finding was
reproducible by in vitro studies using pancreatic cancer cell lines,
in which well-differentiated cell lines had higher PHD3 mRNA
levels than less-differentiated cell lines. In situ localisation of
PHD3 expression was found close to neuronal invasion, but also in
cancer cells. Whether this expression pattern is triggered by
hypoxia only remains to be investigated in further studies as HIF-1
and CAIX did show co-localisation on serial slides, but PHD3 was
not regularly detectable within this very same cellular compart-
ment. To further address the role of PHD3 in tumour growth we
applied two experimental strategies. One strategy was recombinant
overexpression of PHD3 in cell lines constitutively devoid of PHD3
mRNA. The other strategy was siRNA-based downregulation
of PHD3 in cell lines normally expressing PHD3 as determined
qRT-PCR.
In cell culture experiments, cell growth was inhibited by
increasing PHD3 levels and was accelerated by down-regulation
of PHD3 expression especially under conditions of low oxygen.
This effect was not due to HIF-1 activation, as the HIF-1 inhibitor
YC-1 had not effect on cell growth upon PHD3 modulation. Similar
findings were obtained by invasion assays, in which PHD3
exhibited an ‘anti-invasive’ phenotype under conditions of low
oxygen. From cell culture experiments it was obvious that PHD3
over expression clearly changed the cell morphology with the
appearance of stress fibres and floating cells in cell culture
experiments. The presence of stress fibres and phosphorylated
FAK is a marker of focal adhesions that anchor the F-actin
filaments to transmembrane proteins and mediate communication
with the cell’s environment suggesting that PHD3 as oxygen sensor
also influences tumour cell invasion and possibly cell migration
with the biological function of escaping hypoxic areas. This effect
required hydroxylase activity, but was independent of HIF-1.
Another observation was the induction of apoptosis upon PHD3
overexpression and a decreased rate of apoptosis upon PHD3
inhibition. Apparently the proapoptotic effect is mediated by
caspase-3 activation, as the suppression of PHD3 decreased
caspase-3 activity and over expression of PHD3 increased its
activity. One remarkable observation made in human specimens
was the strong immunostaining of ductal cells next to nerves
within the tumour mass. Therefore, we tested the role of NGF in
PHD3-mediated apoptosis. NGF withdrawal strongly suppressed
apoptosis in MIA PaCa-2 and PANC-1 cells. Despite the detailed
mechanism is unknown it appears that the interaction of NGF and
PHD3 is of clinical interest in human specimens, as high levels of
NGF close to neuronal tissue within pancreatic cancer may prevent
these cells to undergo apoptosis. This observation is supported by
a recent finding, in which the human PRP19 protein interacted
with PHD3 to suppress cell death under hypoxic conditions by
limiting the function of PHD3 (Sato et al, 2010).
In experimental pancreatic cancer PHD3 overexpression sup-
pressed tumour growth in both xenografted cell lines when
compared with the control groups. As PHDs represent hypoxic
MIA PaCa-2 PANC-2
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Figure 5 Tumour growth in an orthotopic mouse model of pancreatic
cancer and microvessel density analysis: Xenograft tumours were induced
by transplantation of small tumour fragments derived from a subcutaneous
tumour into the pancreas of nude mice. Stable transfected MIA PaCa-2 and
PANC-1 cell transfected with a PHD3 expression vector or with an empty
pEGFP/N1 were used for subcutaneous tumour induction. After 6 weeks
of tumour growth, PHD3 overexpressing tumours were significantly smaller
than pEGFP/N1-transfected tumours (A). (B) Microvessel density of
tumour xenografts from PANC-1 and MIA PaCa-2 cancer cells was
evaluated by immunostaining for anti-CD31 antibody. Control xenograft
tumours were set as 1. PHD3-overexpressing tumours showed a significant
decrease in microvessel density compared with xenograft tumours derived
from control-transfected tumour cells (B). * indicates Po0.05.
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ssensors regulating HIF-1 and VEGF in vitro we postulated that
PHD3 overexpression and tumour growth inhibition might
represent differences in the angiogenic potential. Therefore, we
assayed neoangiogenesis in these xenografted tumour specimens.
Assessment of intratumoural microvessel density demonstrated
that PHD3 overexpression has an anti-angiogenic effect most likely
by abrogating the VEGF-driven hypoxic angiogenic stimulus as
observed in cell culture experiments.
In summary, we have shown that PHD3 is upregulated in
human pancreatic cancer specimens with the highest average level
found in well-differentiated tumours. Despite the fact that human
tumours grow under conditions of low oxygen, there are most
likely a variety of mechanisms rather than hypoxia causing PHD3
to be roughly 10-fold overexpressed in these specimens. Clearly,
this is in contrast to the in vitro findings, in which PHD3 exerted
tumour-protective functions as well with an increase of apoptosis
and a reduced cell growth rate. Therefore, we speculate that cell
growth retardation of PHD3 and induction of apoptosis are HIF-1-
independent cellular effects of PHD3, whereas the anti-angiogenic
activity is HIF-1 dependent. Clearly, further studies are warranted
in order to address the specific functions of PHD3 in tumour
growth, which may enable us to better estimate a potential benefit
of therapeutic targeting of PHD3. However, the pure fact that
PHD3 is highly overexpressed in human tumour specimens raises
the question, whether PHD3 may represent a suitable target for
therapeutic intervention against pancreatic cancer as its over-
expression caused a dramatic suppression of tumour growth in
experimental pancreatic cancer.
Supplementary Information accompanies the paper on British
Journal of Cancer website (http://www.nature.com/bjc)
REFERENCES
Bruegge K, Jelkmann W, Metzen E (2007) Hydroxylation of hypoxia-
inducible transcription factors and chemical compounds targeting the
HIF-alpha hydroxylases. Curr Med Chem 14: 1853–1862
Buchler P, Gazdhar A, Schubert M, Giese N, Reber HA, Hines OJ, Giese T,
Ceyhan GO, Muller M, Buchler MW, Friess H (2005) The Notch signaling
pathway is related to neurovascular progression of pancreatic cancer.
Ann Surg 242: 791–800, discussion
Buchler P, Gukovskaya AS, Mouria M, Buchler MC, Buchler MW, Friess H,
Pandol SJ, Reber HA, Hines OJ (2003a) Prevention of metastatic
pancreatic cancer growth in vivo by induction of apoptosis with
genistein, a naturally occurring isoflavonoid. Pancreas 26: 264–273
Buchler P, Reber HA, Buchler M, Shrinkante S, Buchler MW, Friess H,
Semenza GL, Hines OJ (2003b) Hypoxia-inducible factor 1 regulates
vascular endothelial growth factor expression in human pancreatic
cancer. Pancreas 26: 56–64
Buchler P, Reber HA, Lavey RS, Tomlinson J, Buchler MW, Friess H, Hines OJ
(2004) Tumor hypoxia correlates with metastatic tumor growth of
pancreatic cancer in an orthotopic murine model. JS u r gR e s120: 295–303
Buchler P, Reber HA, Roth MM, Shiroishi M, Friess H, Hines OJ (2007)
Target therapy using a small molecule inhibitor against angiogenic
receptors in pancreatic cancer. Neoplasia 9: 119–127
Dayan F, Roux D, Brahimi-Horn MC, Pouyssegur J, Mazure NM (2006) The
oxygen sensor factor-inhibiting hypoxia-inducible factor-1 controls
expression of distinct genes through the bifunctional transcriptional
character of hypoxia-inducible factor-1alpha. Cancer Res 66: 3688–3698
El Fitori J, Su Y, Buchler P, Ludwig R, Giese NA, Buchler MW, Quentmeier
H, Hines OJ, Herr I, Friess H (2007) PKC 412 small-molecule tyrosine
kinase inhibitor: single-compound therapy for pancreatic cancer. Cancer
110: 1457–1468
Epstein AC, Gleadle JM, McNeill LA, Hewitson KS, O’Rourke J, Mole DR,
Mukherji M, Metzen E, Wilson MI, Dhanda A, Tian YM, Masson N,
Hamilton DL, Jaakkola P, Barstead R, Hodgkin J, Maxwell PH, Pugh CW,
Schofield CJ, Ratcliffe PJ (2001) C. elegans EGL-9 and mammalian
homologs define a family of dioxygenases that regulate HIF by prolyl
hydroxylation. Cell 107: 43–54
Fu X, Guadagni F, Hoffman RM (1992) A metastatic nude-mouse model of
human pancreatic cancer constructed orthotopically with histologically
intact patient specimens. Proc Natl Acad Sci USA 89: 5645–5649
Gossage L, Zaitoun A, Fareed KR, Turley H, Aloysius M, Lobo DN,
Harris AL, Madhusudan S (2010) Expression of key hypoxia sensing
prolyl-hydroxylases PHD1, -2 and -3 in pancreaticobiliary cancer.
Histopathology 56: 908–920
Graeber TG, Peterson JF, Tsai M, Monica K, Fornace Jr AJ, Giaccia AJ
(1994) Hypoxia induces accumulation of p53 protein, but activation of a
G1-phase checkpoint by low-oxygen conditions is independent of p53
status. Mol Cell Biol 14: 6264–6277
Jaakkola P, Mole DR, Tian YM, Wilson MI, Gielbert J, Gaskell SJ,
Kriegsheim A, Hebestreit HF, Mukherji M, Schofield CJ, Maxwell PH,
Pugh CW, Ratcliffe PJ (2001) Targeting of HIF-alpha to the von Hippel-
Lindau ubiquitylation complex by O2-regulated prolyl hydroxylation.
Science 292: 468–472
Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ (2007) Cancer
statistics, 2007. CA Cancer J Clin 57: 43–66
Lee S, Nakamura E, Yang H, Wei W, Linggi MS, Sajan MP, Farese RV,
Freeman RS, Carter BD, Kaelin Jr WG, Schlisio S (2005) Neuronal
apoptosis linked to EglN3 prolyl hydroxylase and familial pheochromo-
cytoma genes: developmental culling and cancer. Cancer Cell 8: 155–167
Marxsen JH, Stengel P, Doege K, Heikkinen P, Jokilehto T, Wagner T,
Jelkmann W, Jaakkola P, Metzen E (2004) Hypoxia-inducible factor-1
(HIF-1) promotes its degradation by induction of HIF-alpha-prolyl-4-
hydroxylases. Biochem J 381: 761–767
Metzen E, Ratcliffe PJ (2004) HIF hydroxylation and cellular oxygen
sensing. Biol Chem 385: 223–230
Pouyssegur J, Dayan F, Mazure NM (2006) Hypoxia signalling in cancer
and approaches to enforce tumour regression. Nature 441: 437–443
Rankin EB, Giaccia AJ (2008) The role of hypoxia-inducible factors in
tumorigenesis. Cell Death Differ 15: 678–685
Sato M, Sakota M, Nakayama K (2010) Human PRP19 interacts with prolyl-
hydroxylase PHD3 and inhibits cell death in hypoxia. Exp Cell Res 316:
2871–2882
Semenza GL (2007) Hypoxia and cancer. Cancer Metastasis Rev 26: 223–224
Vaupel P, Mayer A, Briest S, Hockel M (2005) Hypoxia in breast cancer:
role of blood flow, oxygen diffusion distances, and anemia in the
development of oxygen depletion. Adv Exp Med Biol 566: 333–342
Vermeulen PB, Gasparini G, Fox SB, Colpaert C, Marson LP, Gion M,
Belien JA, de Waal RM, Van Marck E, Magnani E, Weidner N, Harris AL,
Dirix LY (2002) Second international consensus on the methodology and
criteria of evaluation of angiogenesis quantification in solid human
tumours. Eur J Cancer 38: 1564–1579
Wang GL, Jiang BH, Rue EA, Semenza GL (1995) Hypoxia-inducible factor
1 is a basic-helix-loop-helix-PAS heterodimer regulated by cellular O2
tension. Proc Natl Acad Sci USA 92: 5510–5514
Wang GL, Semenza GL (1995) Purification and characterization of hypoxia-
inducible factor 1. J Biol Chem 270: 1230–1237
Zhu Z, Friess H, diMola FF, Zimmermann A, Graber HU, Korc M,
Buchler MW (1999) Nerve growth factor expression correlates with
perineural invasion and pain in human pancreatic cancer. J Clin Oncol
17: 2419–2428
PHD3: a hypoxic sensor in pancreatic cancer growth
YS uet al
1579
British Journal of Cancer (2010) 103(10), 1571–1579 & 2010 Cancer Research UK
T
r
a
n
s
l
a
t
i
o
n
a
l
T
h
e
r
a
p
e
u
t
i
c
s